2021 American Transplant Congress
Ectopic Hepatocyte Transplantation Into the Lymph Nodes in a Fully Mismatched Allogeneic Dog Model Using Tacrolimus and Prednisone
*Purpose: Develop organogenesis through ectopic hepatocyte transplantation (HT) into the upper abdominal lymph nodes (LN).*Methods: Three groups of Mongrel dogs weighting between 25-35 kg (control…2021 American Transplant Congress
The Learning Curve Associated with De Novo Tacrolimus XR Use in a Racially Diverse Kidney Transplant Population
Medical University of South Carolina, Charleston, SC
*Purpose: Tacrolimus XR (LCP-Tac) was approved for de novo dosing in kidney transplant recipients in 2018. In 2020, our center was challenged with a nationwide…2021 American Transplant Congress
The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients
Medical University of South Carolina, Charleston, SC
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…2021 American Transplant Congress
The Impact of Tacrolimus IPV and TTR on the Development of De Novo Donor-specific Antibodies in Kidney Transplant Recipients
*Purpose: High intrapatient variability (IPV) and low time in therapeutic range (TTR) of tacrolimus (TAC) may increase the risk of developing de novo donor-specific antibodies…2021 American Transplant Congress
Letermovir Prophylaxis in Solid Organ Transplant – CMV Breakthrough and Tacrolimus Drug Interaction
*Purpose: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a…2021 American Transplant Congress
Tacrolimus Dose Requirements in Lung Transplant Recipients on Systemic Azole Antifungals: The Influence of Race and Transplant Indication
*Purpose: CYP3A5 polymorphisms, drug interactions, and alterations in gastric absorption impact tacrolimus metabolism. This is important for those at higher risk of expressing these factors,…2021 American Transplant Congress
Modeling of Alternative Weight-Based Dosing Strategies of LCP-Tacrolimus in De Novo Kidney Transplant Patients
*Purpose: LCP-tacrolimus (LCPT; Envarsus XR®) is a modified-release once-daily formulation approved for prophylaxis of organ rejection in de novo kidney transplant patients in combination with…2021 American Transplant Congress
Safety and Tolerability of Tacrolimus Extended-Release (astagraf Xl) in Hla Sensitized Kidney Transplant Recipients: A Single Center Experience
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Pill burden is a limitation in kidney transplant. Tacrolimus extended-release (Astagraf XL) is a once daily formulation approved for kidney transplantation. Increased compliance could…
- 1
- 2
- 3
- …
- 12
- Next Page »